Filtered By:
Management: Hospitals
Nutrition: Magnesium
This page shows you your search results in order of date.
Order by Relevance | Date
Total 9 results found since Jan 2013.
Electrolyte Imbalance and Neurologic Injury
CNS Neurol Disord Drug Targets. 2023 Feb 15. doi: 10.2174/1871527322666230215144649. Online ahead of print.ABSTRACTNeurologic injury continues to be a debilitating worldwide disease with high morbidity and mortality. The systemic sequelae of a neural insult often lead to prolonged hospital stays and challenging nutritional demands that contribute to poorer prognoses. Clinical management of a given condition should prioritize preserving the homeostatic parameters disrupted by inflammatory response cascades following the primary insult. This focused review examines the reciprocal relationship between electrolyte disturbance ...
Source: CNS and Neurological Disorders Drug Targets - February 15, 2023 Category: Drugs & Pharmacology Authors: Jordan Poe Sai Sriram Yusuf Mehkri Brandon Lucke-Wold Source Type: research
Quantifying the amount of greater brain ischemia protection time with pre-hospital vs. in-hospital neuroprotective agent start
The objective of this study is to quantify the increase in brain-under-protection time that may be achieved with pre-hospital compared with the post-arrival start of neuroprotective therapy among patients undergoing endovascular thrombectomy. In order to do this, a comparative analysis was performed of two randomized trials of neuroprotective agents: (1) pre-hospital strategy: Field administration of stroke therapy-magnesium (FAST–MAG) Trial; (2) in-hospital strategy: Efficacy and safety of nerinetide for the treatment of acute ischemic stroke (ESCAPE-NA1) Trial. In the FAST-MAG trial, among 1,041 acute ischemic stroke p...
Source: Frontiers in Neurology - September 13, 2022 Category: Neurology Source Type: research
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
A Pregnancy Complication to Look out for even after Pregnancy
BY GREGORY TAYLOR, DO, & SHERIF G. EL-ALAYLI, DOA 30-year-old G5P3 presented to the ED with bilateral lower-extremity edema and headache for three days. She presented one week after an uncomplicated full-term vaginal delivery with an unremarkable pregnancy course and no prior requirement for antihypertensive therapy. The headache was described as achy to sharp, with associated photophobia. She also noted occasional vaginal spotting, which was common a few weeks after delivery. She denied any chest pain, shortness of breath, nausea or vomiting, abdominal pain, or any other symptoms. She admitted to occasional mild cr...
Source: The Case Files - August 28, 2018 Category: Emergency Medicine Tags: Blog Posts Source Type: research
Pharmacokinetics of Magnesium in Cardiac Surgery: Implications for Prophylaxis Against Atrial Fibrillation
Postoperative atrial fibrillation (POAF) is the most common cardiovascular complication in patients undergoing cardiac surgery. The risk of POAF depends on the type of procedure, and ranges from 30% in patients undergoing coronary artery bypass surgery to 50% in those undergoing combined procedures. Patients who develop POAF have an increased risk of a number of other complications, including stroke and a prolonged hospital stay, and have a higher risk of death during long-term follow-up.1 The precise mechanism of POAF is unknown, but it is obvious that numerous preoperative, intraoperative, and postoperative factors might...
Source: Journal of Cardiothoracic and Vascular Anesthesia - December 4, 2017 Category: Anesthesiology Authors: Vladimir V. Lomivorotov, Sergey M. Efremov, Alexander M. Karaskov Tags: Editorial Source Type: research
Admission Low Magnesium Level Is Associated with In-Hospital Mortality in Acute Ischemic Stroke Patients
In this study, we investigated the association between magnesium levels on hospital admission and in-hospital mortality in acute ischemic stroke (AIS) patients.Methods: A total of 2,485 AIS patients, enrolled from December 2013 to May 2014 across 22 hospitals in Suzhou city, were included in this study. The patients were divided into 4 groups according to their level of admission magnesium: Q1 (
Source: Cerebrovascular Diseases - April 18, 2017 Category: Neurology Source Type: research
Quick magnesium treatment fails to improve stroke outcomes, but study has silver lining
In the first study of its kind, a consortium led by UCLA physicians found that giving stroke patients intravenous magnesium within an hour of the onset of symptoms does not improve stroke outcomes.
However, the 8-year trial did find that with the help of paramedics in the field, intravenous medications can frequently be administered to stroke victims within that so-called "golden hour," during which they have the best chance to survive and avoid debilitating, long-term neurological damage.
The latter finding is a "game-changer," said Dr. Jeffrey Saver, director of the UCLA Stroke Center and a professor of ...
Source: UCLA Newsroom: Health Sciences - February 13, 2014 Category: Universities & Medical Training Source Type: news
